Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
lusvertikimab (OSE-127)
i
Other names:
OSE-127, Effi-7, MD-707, MD707, Effi7-h, S95011
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
OSE Immunotherapeutics
Drug class:
IL-7R antagonist
‹
›
Associations
(4)
News
Trials
VERI cancer hierarchy
Reset Filters
IL7R expression
B Acute Lymphoblastic Leukemia
IL7R expression
B Acute Lymphoblastic Leukemia
OSE-127
Sensitive: D – Preclinical
OSE-127
Sensitive
:
D
OSE-127
Sensitive: D – Preclinical
OSE-127
Sensitive
:
D
MLL rearrangement
B Acute Lymphoblastic Leukemia
MLL rearrangement
B Acute Lymphoblastic Leukemia
OSE-127
Sensitive: D – Preclinical
OSE-127
Sensitive
:
D
OSE-127
Sensitive: D – Preclinical
OSE-127
Sensitive
:
D
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
OSE-127
Sensitive: D – Preclinical
OSE-127
Sensitive
:
D
OSE-127
Sensitive: D – Preclinical
OSE-127
Sensitive
:
D
TCF3-PBX1 fusion
B Acute Lymphoblastic Leukemia
TCF3-PBX1 fusion
B Acute Lymphoblastic Leukemia
OSE-127
Sensitive: D – Preclinical
OSE-127
Sensitive
:
D
OSE-127
Sensitive: D – Preclinical
OSE-127
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login